{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:57:10Z","timestamp":1764079030212,"version":"3.45.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"DOI":"10.7759\/cureus.97744","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:45:42Z","timestamp":1764078342000},"source":"Crossref","is-referenced-by-count":0,"title":["In Silico Redesign of Epstein-Barr Virus Entry Glycoproteins to Redirect Cellular Tropism as a Foundation for a Novel B Cell Oncolytic Therapy"],"prefix":"10.7759","author":[{"given":"Jeevpreet","family":"Ahluwalia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarush","family":"Katakam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjith","family":"Satish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015, 373:1541-52. 10.1056\/NEJMra1400972","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft N","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, et al.. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018, 32:606-15. 10.1038\/leu.2017.265","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"118","author":"G\u00f6kbuget N","year":"2011","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, et al.. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2011, 118:4571-8. 10.1182\/blood-2011-12-399287","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al.. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017, 376:836-47. 10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell SJ","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012, 30:658-70. 10.1038\/nbt.2287","journal-title":"Nat Biotechnol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman HL","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015, 14:642-62. 10.1038\/nrd4663","journal-title":"Nat Rev Drug Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington K","year":"2019","unstructured":"Harrington K, Freeman DJ, Kelly B, et al.. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019, 18:689-706. 10.1038\/s41573-019-0029-0","journal-title":"Nat Rev Drug Discov"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki O","year":"2020","unstructured":"Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol. 2020, 13:84. 10.1186\/s13045-020-00922-1","journal-title":"J Hematol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson DA","year":"2004","unstructured":"Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004, 350:1328-37. 10.1056\/NEJMra032015","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.14.4510","article-title":"Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2","volume":"81","author":"Fingeroth JD","year":"1984","unstructured":"Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984, 81:4510-4. 10.1073\/pnas.81.14.4510","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.71.6.4657-4662.1997","article-title":"Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes","volume":"71","author":"Li Q","year":"1997","unstructured":"Li Q, Spriggs MK, Kovats S, et al.. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997, 71:4657-62. 10.1128\/JVI.71.6.4657-4662.1997","journal-title":"J Virol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2008.12.010","article-title":"Structure of Epstein-Barr virus glycoprotein 42 suggests a mechanism for triggering receptor-activated virus entry","volume":"17","author":"Kirschner AN","year":"2009","unstructured":"Kirschner AN, Sorem J, Longnecker R, Jardetzky TS. Structure of Epstein-Barr virus glycoprotein 42 suggests a mechanism for triggering receptor-activated virus entry. Structure. 2009, 17:223-33. 10.1016\/j.str.2008.12.010","journal-title":"Structure"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus","volume":"3","author":"Chen J","year":"2018","unstructured":"Chen J, Sathiyamoorthy K, Zhang X, Schaller S, Perez White BE, Jardetzky TS, Longnecker R. Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. Nat Microbiol. 2018, 3:172-80. 10.1038\/s41564-017-0081-7","journal-title":"Nat Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nm0602-594","article-title":"Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus","volume":"8","author":"Borza CM","year":"2002","unstructured":"Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med. 2002, 8:594-9. 10.1038\/nm0602-594","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators","volume":"19","author":"Feederle R","year":"2000","unstructured":"Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000, 19:3080-9. 10.1093\/emboj\/19.12.3080","journal-title":"EMBO J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.1.158-163.1998","article-title":"Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect","volume":"72","author":"Wang X","year":"1998","unstructured":"Wang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol. 1998, 72:158-63. 10.1128\/JVI.72.1.158-163.1998","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and architecture of the EBV B cell entry triggering complex","volume":"10","author":"Sathiyamoorthy K","year":"2014","unstructured":"Sathiyamoorthy K, Jiang J, Hu YX, et al.. Assembly and architecture of the EBV B cell entry triggering complex. PLoS Pathog. 2014, 10:e1004309. 10.1371\/journal.ppat.1004309","journal-title":"PLoS Pathog"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson J","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, et al.. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024, 630:493-500. 10.1038\/s41586-024-07487-w","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1021\/ja026939x","article-title":"HADDOCK: a protein-protein docking approach based on biochemical or biophysical information","volume":"125","author":"Dominguez C","year":"2003","unstructured":"Dominguez C, Boelens R, Bonvin AM. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc. 2003, 125:1731-7. 10.1021\/ja026939x","journal-title":"J Am Chem Soc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nature19946","article-title":"The coming of age of de novo protein design","volume":"537","author":"Huang PS","year":"2016","unstructured":"Huang PS, Boyken SE, Baker D. The coming of age of de novo protein design. Nature. 2016, 537:320-7. 10.1038\/nature19946","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang J","year":"2017","unstructured":"Huang J, Rauscher S, Nawrocki G, et al.. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods. 2017, 14:71-3. 10.1038\/nmeth.4067","journal-title":"Nat Methods"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen EF","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, et al.. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J Comput Chem. 2004, 25:1605-12. 10.1002\/jcc.20084","journal-title":"J Comput Chem"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381270-4.00019-6","article-title":"ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules","volume":"487","author":"Leaver-Fay A","year":"2011","unstructured":"Leaver-Fay A, Tyka M, Lewis SM, et al.. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2011, 487:545-74. 10.1016\/B978-0-12-381270-4.00019-6","journal-title":"Methods Enzymol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki387","article-title":"The FoldX web server: an online force field","volume":"33","author":"Schymkowitz J","year":"2005","unstructured":"Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005, 33:W382-8. 10.1093\/nar\/gki387","journal-title":"Nucleic Acids Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21303","article-title":"Crystal contacts as nature's docking solutions","volume":"31","author":"Krissinel E","year":"2010","unstructured":"Krissinel E. Crystal contacts as nature's docking solutions. J Comput Chem. 2010, 31:133-43. 10.1002\/jcc.21303","journal-title":"J Comput Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005659","article-title":"OpenMM 7: Rapid development of high performance algorithms for molecular dynamics","volume":"13","author":"Eastman P","year":"2017","unstructured":"Eastman P, Swails J, Chodera JD, et al.. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Comput Biol. 2017, 13:e1005659. 10.1371\/journal.pcbi.1005659","journal-title":"PLoS Comput Biol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21787","article-title":"MDAnalysis: a toolkit for the analysis of molecular dynamics simulations","volume":"32","author":"Michaud-Agrawal N","year":"2011","unstructured":"Michaud-Agrawal N, Denning EJ, Woolf TB, Beckstein O. MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. J Comput Chem. 2011, 32:2319-27. 10.1002\/jcc.21787","journal-title":"J Comput Chem"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter JD","year":"2007","unstructured":"Hunter JD. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2007, 9:90-5. 10.1109\/MCSE.2007.55","journal-title":"Comput Sci Eng"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780058880","article-title":"Oncolytic viruses driven by tumor-specific promoters","volume":"7","author":"Hardcastle J","year":"2007","unstructured":"Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets. 2007, 7:181-189. 10.2174\/156800907780058880","journal-title":"Curr Cancer Drug Targets"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02069-w","article-title":"LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion","volume":"21","author":"Xiang Y","year":"2023","unstructured":"Xiang Y, Tian M, Huang J, et al.. LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion. J Nanobiotechnology. 2023, 21:324. 10.1186\/s12951-023-02069-w","journal-title":"J Nanobiotechnology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427655-in-silico-redesign-of-epstein-barr-virus-entry-glycoproteins-to-redirect-cellular-tropism-as-a-foundation-for-a-novel-b-cell-oncolytic-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:45:42Z","timestamp":1764078342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427655-in-silico-redesign-of-epstein-barr-virus-entry-glycoproteins-to-redirect-cellular-tropism-as-a-foundation-for-a-novel-b-cell-oncolytic-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.97744","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}